This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Stifel Nicolaus Sticks to Their Buy Rating for Disc Medicine (IRON)

Tipranks - Tipranks - Tue May 12, 4:12AM CDT

In a report released today, Stephen Willey from Stifel Nicolaus maintained a Buy rating on Disc Medicine, with a price target of $111.00.

Claim 55% Off TipRanks

According to TipRanks, Willey is a 4-star analyst with an average return of 9.6% and a 44.44% success rate. Willey covers the Healthcare sector, focusing on stocks such as Disc Medicine, Incyte, and Insmed.

Disc Medicine has an analyst consensus of Strong Buy, with a price target consensus of $97.67.

See the top stocks recommended by analysts >>

Based on Disc Medicine’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $63.5 million. In comparison, last year the company had a GAAP net loss of $34.09 million

Based on the recent corporate insider activity of 51 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of IRON in relation to earlier this year. Most recently, in February 2026, Jean M. Franchi, the CFO of IRON sold 4,075.00 shares for a total of $256,154.50.

Read More on IRON:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).